SIPA1L1 and breast carcinoma: The best putative candidates in this group were TMEM161A, ERCC2, and SIPA1L1 for overall breast cancer, RNF175 and NCKAP1L for ER-positive disease, and PHAX, SMARCA2, NTRK3, EML5, and MED23 for ER-negative disease.